

Special Issue

Strategies for the Design of Hybrid-Based Antimicrobial Compounds

Message from the Guest Editors

The need for innovative therapeutic strategies to enhance patient outcomes has increased due to the rising threat of multidrug-resistant (MDR) pathogens. In the design of antimicrobial drugs, hybrid molecules containing two or more pharmacophores have emerged as a promising drug design strategy to overcome the issue of MDR. These hybrid molecules display high potential to offer better pharmacokinetic characteristics, suppress resistance mechanisms, and enhance therapeutic outcomes. The aim of this Special Issue is to provide a platform for researchers working on the synthesis, pharmacological evaluation, and mechanistic investigations of synthetic or plant-based hybrid antimicrobial drugs to publish their findings. Authors are invited to contribute their original research articles, reviews, and communications focusing on innovative hybrid molecules targeting bacterial, fungal, and viral infections.

Guest Editors

Dr. Vuyolwethu Khwaza

Dr. Sibusiso Alven

Prof. Dr. Blessing Atim Aderibigbe

Deadline for manuscript submissions

20 September 2025



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/234114

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)